|
|
|
|
| As additional mRNA therapeutics makers progress toward and into the clinic, we're gathering more knowledge about what makes our mRNA products "tick," and how our processes impact the overall quality of our products. Join this expert panel for a timely discussion in the mRNA therapeutics space. Registration is free thanks to the support of Millipore Sigma. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | Overall, there were three main takeaways I gleaned from our conversation that suggest the oligo sector, though more established than its mRNA cousin, is not comfortable with the status quo and is actively trying to grow beyond the limits of its current manufacturing paradigm. Here in part 1, we’ll start with my number one takeaway, which also comes equipped with a bit of history as to how we find ourselves at our current juncture. | |
|
|
|
D. Smith, and P. Stetkiewicz, Arbor Biotechnologies | Following recent news about first-in-human testing, two executives discuss the science and manufacturing strategy for the company's lead candidate, ABO-101. | |
|
|
|
In this Advancing RNA clip, panelists Ulrike Jägle and Tiffany Lucas unpack the benefits they see to the MHRA's new guidance on mRNA cancer immunotherapies, including the agency’s support for bioinformatics approaches and its burgeoning framework for developing and justifying a truly personalized medicine. |
|
|
|
|
|
|
| Building Local Biomanufacturing Capacity In South Africa | White Paper | By J. Brant, and D. Marion, MilliporeSigma | Biovac evolved from a vaccine supplier to a biopharmaceutical innovator, providing a blueprint for expanding Africa's vaccine manufacturing capacity. Gain valuable insights from their journey. |
|
|
| Improving Toxicology Testing For Inhalation Products | Article | Battelle | By embracing new approach methods, regulatory agencies can revolutionize toxicology testing. These methods can be adapted for various medications, including inhalers and nasal-administered drugs. |
|
|
|
| High-Sensitivity IVT mRNA Analysis | Application Note | Agilent Technologies | Quality analysis of in vitro transcribed (IVT) has become an essential part of biotherapeutic workflows. Discover a high-sensitivity kit made for analyzing IVT mRNA quality to advance your research. |
|
|
|
|
| Secure your spot for AMM ASCENT, September 16 - 18! Join senior executives and top decision-makers for timely discussions, from What’s Next After Baby KJ? The Future of mRNA in Gene Editing and Rare Disease, to Innovation in mRNA Cancer Immunotherapies, to Global Industry Outlook. You won’t want to miss this event. Review the speaker lineup, agenda, and book your stay! |
|
|
.png){kind=logo}
